Snapshot
Abbott Laboratories reported $11.46B of revenue in Q4 2025, up 4.4% year over year, with diluted EPS of $1.01 and an operating margin of 19.6%.
- Revenue
- $11.46B
- YoY growth
- +4.4%
- Diluted EPS
- $1.01
- Operating margin
- 19.6%
$11.46B
Revenue
+4.4%
YoY growth
$1.01
Diluted EPS
19.6%
Operating margin
01 Key takeaways
What management said
- •These Non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com.
- •Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which is defined in the press release issued earlier today.
- •We delivered top-tier margin expansion and achieved our original target of double-digit earnings growth in earnings per share despite the implementation of new tariffs and heightened market challenges in China.
- •Our announced acquisition of Exact Sciences will allow Abbott to enter and lead in the fast-growing cancer diagnostics market and adds a new high-growth business with an attractive pipeline to the Abbott portfolio.
- •As we announced this morning, we forecast the midpoint of our 2026 organic sales growth range to be 7% and the midpoint of our adjusted earnings per share range to reflect 10% growth.
- •Abbott has been in the nutrition business for more than 60 years, and with that history comes experience, not just in times of growth, but in times that require navigating challenges.
- •Our results this quarter underscore a broader challenge, which is the need to reignite volume growth, a challenge many consumer goods businesses face today.
- •We have increased prices to help mitigate the impact of higher manufacturing costs, but those price increases in the current economic environment have become a factor in constraining volume growth.
- •Higher manufacturing costs led to higher prices, which in turn are suppressing demand as consumers become increasingly more price-sensitive.
- •Our goal is to transition our business back to one with a more balanced growth profile, with volume growth playing a greater role going forward.
- •In the fourth quarter, we began implementing price and promotion initiatives to help start the process of reigniting volume growth.
- •We expect performance in the nutrition to remain challenged in the first half of the year, with a return to growth in the second half.
SourcesCompany financials · earnings call
Last updated